We provide evidence that the scDb-hERG1-β1-TRAIL antibody can induce apoptotic cell death both in vitro and in vivo in breast cancer cells, sparing normal cells, with particular efficacy in triple-negative breast cancer (TNBC) cells which express the hERG1/β1 integrin complex. Here, TNFSF10 is linked to breast carcinoma.